Table 3.

Associations of RAS inhibitor use with AD pathology.

RAS inhibitor use	Estimate (SE, p‐value)
	Global AD score	Amyloid burden	Tau tangle density
During the study	−0.165 (0.100, 0.099)	−0.048 (0.170, 0.780)	−0.425 (0.184, 0.022)
During last 5 years of life	−0.093 (0.097, 0.338)	−0.148 (0.164, 0.369)	−0.245 (0.180, 0.177)

Each linear regression model with individual AD pathology measure as the outcome has been adjusted for age at death, sex, and diabetes. Bold values denote statistical significance (p < 0.05).